Advertisement
Screener

AYTU BIOPHARMA, INC (AYTU) Operating Lease, Payments

2.8 / 5 stars · 68/120 Roast Me

AYTU BIOPHARMA, INC Operating Lease, Payments

AYTU BIOPHARMA, INC (AYTU) reported Operating Lease, Payments of $182.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:OperatingLeasePayments · last filed 2026-09-22

  • AYTU BIOPHARMA, INC operating lease, payments for the quarter ending 2026-06-30 was $82.00K, a 51.85% increase year-over-year.
  • AYTU BIOPHARMA, INC operating lease, payments for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
  • AYTU BIOPHARMA, INC operating lease, payments for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
  • AYTU BIOPHARMA, INC operating lease, payments for the quarter ending 2025-09-30 was $100.00K, a 50.00% decline year-over-year.
  • AYTU BIOPHARMA, INC operating lease, payments for fiscal 2026 was $182.00K, a 75.86% decline from fiscal 2025.
  • AYTU BIOPHARMA, INC operating lease, payments for fiscal 2025 was $754.00K, a 56.24% decline from fiscal 2024.
  • AYTU BIOPHARMA, INC operating lease, payments for fiscal 2024 was $1.72M, a 19.99% increase from fiscal 2023.
  • AYTU BIOPHARMA, INC operating lease, payments for fiscal 2023 was $1.44M, a 41.34% increase from fiscal 2022.
Period endOperating Lease, Payments 3 monthOperating Lease, Payments 3 month as first filedOperating Lease, Payments 6 monthOperating Lease, Payments 6 month as first filedOperating Lease, Payments 9 monthOperating Lease, Payments 9 month as first filedOperating Lease, Payments 12 monthOperating Lease, Payments 12 month as first filed
2026-06-30$82.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22
$82.00K
derived: sum of 2 quarters · filed 2026-09-22
$82.00K
derived: sum of 3 quarters · filed 2026-09-22
$182.00K
10-K · filed 2026-09-22
2026-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13
$0.00
derived: sum of 2 quarters · filed 2026-05-13
$100.00K
10-Q · filed 2026-05-13
$154.00K
derived: sum of 4 quarters · filed 2026-09-22
2025-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03
$100.00K
10-Q · filed 2026-02-03
$154.00K
derived: sum of 3 quarters · filed 2026-09-22
$254.00K
derived: sum of 4 quarters · filed 2026-09-22
2025-09-30$100.00K
10-Q · filed 2025-11-13
$154.00K
derived: sum of 2 quarters · filed 2026-09-22
$254.00K
derived: sum of 3 quarters · filed 2026-09-22
$654.00K
derived: sum of 4 quarters · filed 2026-09-22
2025-06-30$54.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22
$154.00K
derived: sum of 2 quarters · filed 2026-09-22
$554.00K
derived: sum of 3 quarters · filed 2026-09-22
$754.00K
10-K · filed 2026-09-22
2025-03-31$100.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13
$500.00K
derived: sum of 2 quarters · filed 2026-05-13
$700.00K
10-Q · filed 2026-05-13
$739.00K
10-Q · filed 2025-05-14
$1.39M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$400.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03
$600.00K
10-Q · filed 2026-02-03
$606.00K
10-Q · filed 2025-02-12
$1.29M
derived: sum of 3 quarters · filed 2026-02-03
$1.63M
derived: sum of 4 quarters · filed 2026-02-03
2024-09-30$200.00K
10-Q · filed 2025-11-13
$168.00K
10-Q · filed 2024-11-13
$889.00K
derived: sum of 2 quarters · filed 2025-11-13
$1.23M
derived: sum of 3 quarters · filed 2025-11-13
$1.56M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$689.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23
$1.03M
derived: sum of 2 quarters · filed 2025-09-23
$1.36M
derived: sum of 3 quarters · filed 2025-09-23
$1.72M
10-K · filed 2025-09-23
$1.81M
10-K · filed 2024-09-26
2024-03-31$337.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14
$674.00K
derived: sum of 2 quarters · filed 2025-05-14
$1.03M
10-Q · filed 2025-05-14
$1.39M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$337.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12
$697.00K
10-Q · filed 2025-02-12
$1.06M
derived: sum of 3 quarters · filed 2025-02-12
$1.42M
derived: sum of 4 quarters · filed 2025-02-12
2023-09-30$360.00K
10-Q · filed 2024-11-13
$720.00K
derived: sum of 2 quarters · filed 2024-11-13
$1.08M
derived: sum of 3 quarters · filed 2024-11-13
$1.44M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$360.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26
$720.00K
derived: sum of 2 quarters · filed 2024-09-26
$1.08M
derived: sum of 3 quarters · filed 2024-09-26
$1.44M
10-K · filed 2024-09-26
2023-03-31$360.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15
$719.00K
derived: sum of 2 quarters · filed 2024-05-15
$1.08M
10-Q · filed 2024-05-15
$1.15M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31$359.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14
$716.00K
10-Q · filed 2024-02-14
$790.00K
derived: sum of 3 quarters · filed 2024-02-14
$1.15M
derived: sum of 4 quarters · filed 2024-02-14
2022-09-30$357.00K
10-Q · filed 2023-11-14
$431.00K
derived: sum of 2 quarters · filed 2023-11-14
$788.00K
derived: sum of 3 quarters · filed 2023-11-14
$1.09M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$74.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12
$431.00K
derived: sum of 2 quarters · filed 2023-10-12
$734.00K
derived: sum of 3 quarters · filed 2023-10-12
$1.02M
10-K · filed 2023-10-12
2022-03-31$357.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11
$660.00K
derived: sum of 2 quarters · filed 2023-05-11
$942.00K
10-Q · filed 2023-05-11
$1.21M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$303.00K
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21
$585.00K
10-Q · filed 2023-02-21
$857.00K
derived: sum of 3 quarters · filed 2023-02-21
$927.00K
derived: sum of 4 quarters · filed 2023-02-21
2021-09-30$282.00K
10-Q/A · filed 2023-02-21
$554.00K
derived: sum of 2 quarters · filed 2023-02-21
$624.00K
derived: sum of 3 quarters · filed 2023-02-21
$654.00K
derived: sum of 4 quarters · filed 2023-02-21
2021-06-30$272.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27
$342.00K
derived: sum of 2 quarters · filed 2022-09-27
$372.00K
derived: sum of 3 quarters · filed 2022-09-27
$467.00K
10-K · filed 2022-09-27
2021-03-31$70.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16
$100.00K
derived: sum of 2 quarters · filed 2022-05-16
$195.00K
10-Q · filed 2022-05-16
$128.00K
10-Q · filed 2021-05-17
$322.00K
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$30.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14
$125.00K
10-Q · filed 2022-02-14
$147.00K
10-Q · filed 2021-02-11
$252.00K
derived: sum of 3 quarters · filed 2022-02-14
$261.00K
derived: sum of 4 quarters · filed 2022-02-14
2020-09-30$95.00K
10-Q · filed 2021-11-15
$66.00K
10-Q · filed 2020-11-12
$222.00K
derived: sum of 2 quarters · filed 2021-11-15
$231.00K
derived: sum of 3 quarters · filed 2021-11-15
$294.00K
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$127.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28
$136.00K
derived: sum of 2 quarters · filed 2021-09-28
$199.00K
derived: sum of 3 quarters · filed 2021-09-28
$199.00K
10-K · filed 2021-09-28
2020-03-31$9.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17
$72.00K
derived: sum of 2 quarters · filed 2021-05-17
$72.00K
10-Q · filed 2021-05-17
2019-12-31$63.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11
$63.00K
10-Q · filed 2021-02-11
2019-09-30$0.00
10-Q · filed 2020-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77